Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 6;25:81. doi: 10.1186/s13058-023-01679-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Antitumor activity of DZD1516 in BM, LM, and subcutaneous BT474C1-Luci Mono1 xenograft mice model. The BT474C1-Luci Mono1 cell model was a stable clone generated by transfection of luciferase gene into BT474 cell line and selection of stable clones. The mice were treated with DZD1516 at 100 mg/kg and 150 mg/kg twice daily, respectively, after tumors were established. A Plots of tumor volume in BM model. The statistical analysis of tumor volume difference at week 3 between DZD1516 and tucatinib groups was performed by two-way ANOVA, compared with the tucatinib group. ****P < 0.0001, ns: not significant. B Representative images of bioluminescent signals at week 0 and week 3 after the start of compound treatment in BM model. C Plots of tumor volume in LM model. D Representative images of bioluminescent signals at week 0 and week 2 after the start of compound treatment in LM model. E Plots of tumor volume in subcutaneous model. BM brain metastasis, LM leptomeningeal metastasis. BID: twice daily